Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorHaukeland University Hospital
About this trial
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis.
The main question it aims to answer is:
• Does NR delay disability progression in progressive multiple sclerosis?
Participants will be treated with NR or placebo for 30 months,
Eligibility criteria
Qualifiers
A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria.
Aged 18-65 years.
EDSS 3-6.5
Able to perform T25FW test
Disqualifiers
A diagnosis of relapsing MS according to the revisions of the McDonald criteria
Neoplastic disease at baseline
Previous history of malignant melanoma or breast cancer
Stable phase of a progressive disease course
Trial design
Treatments tested in this trial
- Nicotinamid riboside
- Placebo
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov